key: cord-0777663-9zlxh558 authors: Huang, Lei; Liang, Peipei; Xu, Yuanhong; Xu, Aman; Wei, Zhijian title: Development of coagulation disorders, malnutrition, and anaemia and duration of virus shedding in COVID‐19: Implications for disease mechanism and management date: 2021-08-13 journal: Int J Clin Pract DOI: 10.1111/ijcp.14353 sha: 9802b79afdd0f8e29d362addd2870c1551efe7c4 doc_id: 777663 cord_uid: 9zlxh558 nan The full spectrum of COVID-19 remains unclear. [1] [2] [3] [4] [5] [6] [7] [8] In this report, we investigated the evolution of laboratory findings across disease course, focussing on the coagulation and nutrition aspects, and duration of virus shedding in patients with confirmed COVID-19, and compared features stratified by duration of virus shedding. Methods and Materials are detailed in the Supporting Information. Of the 21 enrolled patients with COVID-19, the median duration of SARS-CoV-2 shedding was 11 days, and nine patients (43%) had a shedding period ≥14 days ( Figure 1 ). The average probability of SARS-CoV-2 shedding was 76% 1 week after illness-onset, and dropped to 38% and 14% at the end of the second and third week, respectively; the probability was 5% 4 weeks after illnessonset. Patients with duration of SARS-CoV-2 shedding ≥14 days had more lymphocytes in peripheral-blood (1.58 vs 1.09 ×10 9 /L), higher alkaline-phosphatase levels (63 vs 50 U/L), and less often increased C-reactive protein levels (13% vs 75%; Tables S3). Other features and features stratified by sex, age-group, and duration of SARS-CoV-2 shedding are described in Supporting Information. The time interval between illness-onset and first blood sample collection was classified into four categories (≤3, 4-6, 7-9 and ≥10 days; Figures 2A and S1 ). With longer intervals, haematocrit decreased especially within 10 days after illness-onset. Fibrinogen, fibrinogen degradation products, and d-dimer increased within 10 days after onset, and decreased afterwards. Albumin levels markedly decreased after illness Day 4. Serum total bilirubin and creatinine levels markedly increased 10 days after illness-onset, following beforehand decreasing concentrations. Bicarbonate and calcium levels showed decreasing trends. Levels of myoglobin, creatine-kinase, and creatine-kinase-isoenzyme-MB increased, especially 10 days after onset. C-reactive-protein markedly increased starting from 7 days after onset. The median time from illness-onset to first blood sample collection was 5 days, and afterwards blood was sampled every 3 days for laboratory evaluations (median intervals between illness-onset and second, third, fourth, and fifth sampling: 8, 11, 14, and 17 days; (Table S3) • Development of coagulation-fibrinolysis disorders, malnutrition, and anaemia, which may be associated with various serious events in COVID-19, was observed and should be closely monitored during disease progression and intervened when necessary. COVID-19, and on average a total quarantine period of 4 weeks from illness-onset is recommended. • Decreased lymphocyte count and increased C-reactive protein level on admission may indicate more active disease-related immune/inflammatory response. days; Group 2, interval 4-6 days; Group 3, interval 7-9 days; and Group 4, interval ≥10 days. (B) Dynamic changes of laboratory findings by times of blood sample collection. The median time from illness-onset to first blood sample collection was 5 days and afterwards blood was sampled every 3 days (median intervals between illness-onset and second, third, fourth and fifth sampling: 8, 11, 14 and 17 days) • Our findings may have important implications for disease mechanism and management. Anhui Medical University (YJGG202002). We thank the patients and contacts; all healthcare workers and hospitals who provide care for patients with COVID-19 and are involved in the diagnosis and treatment of COVID-19 patients and those who trace and quarantine the contacts; staff at the local, city, and province healthcare departments; members of the COVID-19 response teams at the local, city, province, and national levels; and medical institutions in Hefei for assistance with data collection. We declare no competing interests. The data that support the findings of this study are available from the corresponding authors on reasonable request. Anonymous participant data without names and identifiers can be provided after approval by the corresponding authors and healthcare authorities. After publication of study findings, the data will be available for others to request. The proposal with detailed description of research objectives and analysis plan will be needed for evaluation of the reasonability to request for our data. The corresponding authors and healthcare authorities will make a decision based on these materials regarding whether to share the data or not. Additional materials may also be required during the process. The data that support the findings of this study are available from the corresponding authors on reasonable request. Anonymous participant data without names and identifiers can be provided after approval by the corresponding authors and healthcare authorities. After publication of study findings, the data will be available for others to request. The proposal with detailed description of research objectives and analysis plan will be needed for evaluation of the reasonability to request for our data. The corresponding authors and healthcare authorities will make a decision based on these materials regarding whether to share the data or not. Additional materials may also be required during the process. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study Effectiveness of interventions as part of the One Health approach to control coronavirus disease 2019 and stratified case features in Anhui Province, China: a real-world populationbased cohort study. One Health Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A novel coronavirus from patients with pneumonia in China Novel coronavirus in the United States WHO. Coronavirus Disease (COVID-19) Outbreak WHO. Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus detai l/30-01-2020-state ment-on-the-secon d-meeti ng-of-the-inter natio nal-healt h-regul ation s-(2005)-emerg ency-commi ttee-regar ding-the-outbr eak-of-novel Development of coagulation disorders, malnutrition, and anaemia and duration of virus shedding in COVID-19: Implications for disease mechanism and management